Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Partners Group
Deal Size : $1,900.0 million
Deal Type : Acquisition
Partners Group to Acquire Pharmathen, a Leading European Pharmaceutical Company, from BC Partners
Details : On acquisition, Partners Group will work to strengthen Pharmathen’s business in Europe and the US, especially R&D, sustained release’ technologies, including long-acting injectables, slow-releasing oral drugs and ophthalmics segment.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 19, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Partners Group
Deal Size : $1,900.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.